Trial Profile

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Carboplatin (Primary) ; Doxorubicin (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Gefitinib (Primary) ; Gemcitabine (Primary) ; Letrozole (Primary) ; Olaparib (Primary) ; Osimertinib (Primary) ; Pemetrexed (Primary) ; Tamoxifen (Primary) ; Temozolomide (Primary)
Indications Advanced breast cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
Focus Therapeutic Use
Acronyms SMMART-ACT

Most Recent Events

13 Jun 2025 Planned initiation date changed from 1 Mar 2025 to 16 Jun 2025.
13 Feb 2025 Planned initiation date changed from 1 Feb 2025 to 1 Mar 2025.
18 Dec 2024 Planned number of patients changed from 38 to 30.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com